Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Do Avandia Benefits Outweigh Risks? AHRQ, Consumer Reports Are Skeptical

Executive Summary

An Agency for Healthcare Research & Quality report concluding thiazolidinediones are no more efficacious than metformin could put formulary pressure on the two marketed products in the class -GlaxoSmithKline's Avandia (rosiglitazone) and Lilly/Takeda's Actos (pioglitazone)

You may also be interested in...

Avandia, Actos Add Black Box; RECORD Leaves Heart Attack Risk Unresolved

FDA is adding a "black box" warning about the risk of congestive heart failure to thiazolidinediones while it continues to evaluate the potential risk of myocardial infarction seen in the class of type 2 diabetes therapies

FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal

FDA is not taking immediate regulatory action on an observed cardiovascular signal for GlaxoSmithKline's Avandia, as the agency feels the current labeling is sufficient until its own analysis of emerging safety data for the type 2 diabetes therapy is completed

Diabetes Drugs Under Part D: Pfizer Exubera Slow To Gain Formulary Traction

Pfizer's inhaled insulin Exubera is not being covered by many national Part D plans, and plans that do cover Exubera put it on higher copay tiers and require patients to obtain authorization before getting it, an analysis of 2007 Part D plan coverage of diabetes medications by F-D-C Reports' Medicare Drug Focus shows

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts